Resveratrol Augments Doxorubicin and Cisplatin Chemotherapy: A Novel Therapeutic Strategy

Basit Öğe Kaydı
dc.authoridKhan, Prof. Dr. Haroon/0000-0002-1736-4404
dc.authoridZarrabi, Ali/0000-0003-0391-1769
dc.authoridAshrafizadeh, Milad/0000-0001-6605-822X
dc.authoridFives, Kaila/0009-0006-5836-0377
dc.authorwosidMirzaei, Sepideh/AAB-1637-2022
dc.authorwosidKhan, Prof. Dr. Haroon/AAY-1785-2020
dc.authorwosidZarrabi, Ali/U-2602-2019
dc.authorwosidAshrafizadeh, Milad/JGC-9775-2023
dc.contributor.authorMirzaei, Sepideh
dc.contributor.authorGholami, Mohammad Hossein
dc.contributor.authorZabolian, Amirhossein
dc.contributor.authorSaleki, Hossein
dc.contributor.authorBagherian, Morteza
dc.contributor.authorTorabi, Seyed Mohammadreza
dc.contributor.authorSharifzadeh, Seyed Omid
dc.date.accessioned2024-05-19T14:46:31Z
dc.date.available2024-05-19T14:46:31Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBackground The treatment of cancer is a current challenge for public health, causing high rates of morbidity and mortality worldwide. Doxorubicin (DOX) and cisplatin (CP) are two well-known chemotherapeutic agents approved by the Food and Drug Administration to treat cancer patients. However, there are two problems associated with DOX and CP: drug resistance and adverse impact. Resveratrol (Res) belongs to the stilbene class and possesses various health-promoting effects, such as antioxidant, anti-inflammatory, anticancer, hepatoprotective, and neuroprotective effects. Objective The present review aims to give special attention to the therapeutic impacts of Res in potentiating DOX and CP's antitumor activities and reducing their side effects. Methods PubMed, Science Direct, and Google Scholar were used to search articles for the current manuscripts. Results Co-administration of Res can prevent chemoresistance and potentiate the induction of apoptosis and cell cycle arrest in cancer cells. Res can enhance the sensitivity of cancer cells to DOX and CP chemotherapy by inhibiting the migration and metastasis of cancer cells. Simultaneously, Res, due to its therapeutic actions ameliorates the adverse impacts of DOX and CP on normal cells and organs, including the liver, kidney, brain, and testes. As Res suffers from poor bioavailability, nanoformulations have been developed with promising results to improve its antitumor activity and protective effects. Conclusion Based on preclinical studies, it is obvious that Res is a promising adjsuvant for CP and DOX chemotherapy, and its benefits can be utilized in the clinical course.en_US
dc.identifier.doi10.2174/1874467215666220415131344
dc.identifier.endpage306en_US
dc.identifier.issn1874-4672
dc.identifier.issn1874-4702
dc.identifier.issue3en_US
dc.identifier.pmid35430977en_US
dc.identifier.scopus2-s2.0-85149216134en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage280en_US
dc.identifier.urihttps://doi.org10.2174/1874467215666220415131344
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5540
dc.identifier.volume16en_US
dc.identifier.wosWOS:000947246500003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofCurrent Molecular Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectResveratrolen_US
dc.subjectDoxorubicinen_US
dc.subjectCisplatinen_US
dc.subjectCancer Chemotherapyen_US
dc.subjectChemoresistanceen_US
dc.subjectChemoprotectionen_US
dc.subjectAntitumor Activityen_US
dc.titleResveratrol Augments Doxorubicin and Cisplatin Chemotherapy: A Novel Therapeutic Strategyen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu